These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 4058585)
1. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Buller RM; Smith GL; Cremer K; Notkins AL; Moss B Nature; 1985 Oct 31-Nov 6; 317(6040):813-5. PubMed ID: 4058585 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the virulence of wild-type thymidine kinase (tk)-deficient and tk+ phenotypes of vaccinia virus recombinants after intranasal inoculation of mice. Taylor G; Stott EJ; Wertz G; Ball A J Gen Virol; 1991 Jan; 72 ( Pt 1)():125-30. PubMed ID: 1990060 [TBL] [Abstract][Full Text] [Related]
3. Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Paoletti E; Lipinskas BR; Samsonoff C; Mercer S; Panicali D Proc Natl Acad Sci U S A; 1984 Jan; 81(1):193-7. PubMed ID: 6320164 [TBL] [Abstract][Full Text] [Related]
7. Secondary vaccination with vaccinia virus recombinants: role of residual virulence of recombinants and immunogenicity of extrinsic antigens. Kutinová L; Ludvíková V; Nemecková S; Hainz P; Simonová V; Vonka V Vaccine; 1999 Mar; 17(9-10):1186-92. PubMed ID: 10195631 [TBL] [Abstract][Full Text] [Related]
8. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. McCart JA; Ward JM; Lee J; Hu Y; Alexander HR; Libutti SK; Moss B; Bartlett DL Cancer Res; 2001 Dec; 61(24):8751-7. PubMed ID: 11751395 [TBL] [Abstract][Full Text] [Related]
9. Construction of vaccinia virus recombinants expressing several measles virus proteins and analysis of their efficacy in vaccination of mice. Wild TF; Bernard A; Spehner D; Drillien R J Gen Virol; 1992 Feb; 73 ( Pt 2)():359-67. PubMed ID: 1538193 [TBL] [Abstract][Full Text] [Related]
10. Improved safety of a replication-competent poxvirus-based HIV vaccine with the introduction of the HSV-TK/GCV suicide gene system. Zhang Q; Liu Z; Hou J; Wang S; Liu C; Wei M; Liu Y; Shao Y Vaccine; 2016 Jun; 34(30):3447-53. PubMed ID: 27195760 [TBL] [Abstract][Full Text] [Related]
11. Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2. Flexner C; Moss B; London WT; Murphy BR Vaccine; 1990 Feb; 8(1):17-21. PubMed ID: 2316280 [TBL] [Abstract][Full Text] [Related]
12. Construction of recombinant fowlpox viruses as vectors for poultry vaccines. Boyle DB; Coupar BE Virus Res; 1988 Jun; 10(4):343-56. PubMed ID: 2842977 [TBL] [Abstract][Full Text] [Related]
13. Molecular attenuation of vaccinia virus: mutant generation and animal characterization. Lee MS; Roos JM; McGuigan LC; Smith KA; Cormier N; Cohen LK; Roberts BE; Payne LG J Virol; 1992 May; 66(5):2617-30. PubMed ID: 1560521 [TBL] [Abstract][Full Text] [Related]
14. Recombinant vaccinia virus LC16m0 or LC16m8 that expresses hepatitis B surface antigen while preserving the attenuation of the parental virus strain. Morita M; Suzuki K; Yasuda A; Kojima A; Sugimoto M; Watanabe K; Kobayashi H; Kajima K; Hashizume S Vaccine; 1987 Mar; 5(1):65-70. PubMed ID: 3554809 [TBL] [Abstract][Full Text] [Related]
15. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Panicali D; Paoletti E Proc Natl Acad Sci U S A; 1982 Aug; 79(16):4927-31. PubMed ID: 6289324 [TBL] [Abstract][Full Text] [Related]
16. Attenuated deletion mutants of vaccinia virus lacking the vaccinia growth factor are defective in replication in vivo. Lai AC; Pogo BG Microb Pathog; 1989 Mar; 6(3):219-26. PubMed ID: 2739561 [TBL] [Abstract][Full Text] [Related]
17. Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes. Legrand FA; Verardi PH; Jones LA; Chan KS; Peng Y; Yilma TD J Virol; 2004 Mar; 78(6):2770-9. PubMed ID: 14990697 [TBL] [Abstract][Full Text] [Related]
18. Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. Williamson JD; Reith RW; Jeffrey LJ; Arrand JR; Mackett M J Gen Virol; 1990 Nov; 71 ( Pt 11)():2761-7. PubMed ID: 2254756 [TBL] [Abstract][Full Text] [Related]
19. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Ramshaw IA; Andrew ME; Phillips SM; Boyle DB; Coupar BE Nature; 1987 Oct 8-14; 329(6139):545-6. PubMed ID: 3498904 [TBL] [Abstract][Full Text] [Related]
20. Humoral and cell-mediated immune responses to recombinant vaccinia viruses in mice. Andrew ME; Coupar BE; Boyle DB Immunol Cell Biol; 1989 Oct; 67 ( Pt 5)():331-7. PubMed ID: 2613280 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]